

August 03, 2023

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Incorporation of a Step Down Subsidiary

Pursuant to Regulation 30 of the SEBI Listing Regulations, we would like to inform that the Board of Directors of Caplin Steriles Limited, a material Subsidiary of the Company, had approved the incorporation of a wholly owned subsidiary in the US, at the meeting of its Board held yesterday i.e. August 02, 2023.

The details required under regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A.

Kindly take the same on record.

Thanking You,

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary
Membership No. A23989

Encl: A/a

Annexure – A

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	Name of the Step-down Subsidiary: Caplin Steriles USA Inc, or such other name as may be approved by the statutory authorities in the state of Delaware. Share Capital: The initial share capital is expected to be USD 5,00,000.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length	The Step-down Subsidiary, once incorporated, will be a related party of the company and other subsidiaries. Except the above, the Promoter/ promoter group/ group companies does not have interested in the transaction.
3.	Industry to which the entity being acquired belongs	Marketing and Distribution of Pharmaceutical products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed Step-down Subsidiary shall be the front end entity for Caplin Steriles Limited in the US for direct sales, marketing and distribution of the products manufactured by Caplin Steriles Limited.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable.
6.	Indicative time period for completion of the acquisition	Incorporation is expected to be completed within the next four weeks.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	The initial share capital will be paid by way of cash consideration.
8.	Cost of acquisition and/or the price at which the shares are acquired	Not Applicable. Upon incorporation, the contribution to initial share capital will be made at face value.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	The proposed company would be Wholly-owned Subsidiary of Caplin Steriles Limited which is in turn a 99.99% Subsidiary of the Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years’ turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable since the company is yet to be incorporated